DE69306940T3 - 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe - Google Patents

3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe

Info

Publication number
DE69306940T3
DE69306940T3 DE69306940T DE69306940T DE69306940T3 DE 69306940 T3 DE69306940 T3 DE 69306940T3 DE 69306940 T DE69306940 T DE 69306940T DE 69306940 T DE69306940 T DE 69306940T DE 69306940 T3 DE69306940 T3 DE 69306940T3
Authority
DE
Germany
Prior art keywords
monophosphoryl lipid
vaccines containing
deacylated monophosphoryl
hepatitis vaccines
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69306940T
Other languages
English (en)
Other versions
DE69306940T2 (de
DE69306940D1 (de
Inventor
Nathalie Marie- Garcon-Johnson
Pierre Hauser
Clothilde Thiriart
Pierre Voet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69306940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Application filed by GlaxoSmithKline Biologicals SA, SmithKline Beecham Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE69306940D1 publication Critical patent/DE69306940D1/de
Publication of DE69306940T2 publication Critical patent/DE69306940T2/de
Application granted granted Critical
Publication of DE69306940T3 publication Critical patent/DE69306940T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69306940T 1992-03-27 1993-03-24 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe Expired - Lifetime DE69306940T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
PCT/EP1993/000712 WO1993019780A1 (en) 1992-03-27 1993-03-24 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a

Publications (3)

Publication Number Publication Date
DE69306940D1 DE69306940D1 (de) 1997-02-06
DE69306940T2 DE69306940T2 (de) 1997-06-26
DE69306940T3 true DE69306940T3 (de) 2002-09-19

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69306940T Expired - Lifetime DE69306940T3 (de) 1992-03-27 1993-03-24 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe

Country Status (28)

Country Link
EP (1) EP0633784B2 (de)
JP (1) JP3470719B2 (de)
KR (1) KR100270134B1 (de)
CN (1) CN1072963C (de)
AP (1) AP570A (de)
AT (1) ATE146678T1 (de)
AU (4) AU3751693A (de)
CA (1) CA2132833C (de)
CZ (1) CZ283424B6 (de)
DE (1) DE69306940T3 (de)
DK (1) DK0633784T4 (de)
ES (1) ES2098029T5 (de)
FI (1) FI110843B (de)
GR (1) GR3022174T3 (de)
HK (1) HK1003218A1 (de)
HU (1) HU221253B1 (de)
IL (1) IL105161A (de)
MA (1) MA22842A1 (de)
MY (1) MY111880A (de)
NO (1) NO309458B1 (de)
NZ (1) NZ249868A (de)
RU (1) RU2121849C1 (de)
SA (1) SA93130573B1 (de)
SG (1) SG48375A1 (de)
SI (1) SI9300149B (de)
SK (1) SK280160B6 (de)
UA (1) UA44688C2 (de)
WO (1) WO1993019780A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
HU219056B (hu) * 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2305294B1 (de) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
JP5869744B2 (ja) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
EP2004226A1 (de) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Lagerung von grippeimpfstoffen ohne kühlung
EP2476434A1 (de) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2687228B1 (de) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Impfstoff mit streptococcus pneumoniae-kapsulären polysaccharid-konjugaten
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2710480A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
ES2671880T3 (es) * 2009-03-05 2018-06-11 Jenny Colleen Mccloskey Tratamiento de infección
DK3178490T3 (da) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2646459B1 (de) 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
EP3527224A1 (de) 2011-01-26 2019-08-21 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
EP2859011B1 (de) 2012-06-06 2019-12-11 Bionor Immuno AS Peptide aus viralen proteinen zur verwendung als immunogene oder nachweisreagenzien
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
ES2012739T5 (es) * 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0414374B1 (de) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigene sowie Verfahren zu deren Herstellung
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
WO1992011291A1 (en) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen

Also Published As

Publication number Publication date
GR3022174T3 (en) 1997-03-31
HK1003218A1 (en) 1998-10-16
CA2132833A1 (en) 1993-10-14
ES2098029T5 (es) 2002-03-16
HU9402758D0 (en) 1994-12-28
AU1000802A (en) 2002-02-21
AP570A (en) 1996-11-29
FI110843B (fi) 2003-04-15
NZ249868A (en) 1997-03-24
CZ235594A3 (en) 1995-02-15
RU2121849C1 (ru) 1998-11-20
AU3397499A (en) 1999-08-19
AU3751693A (en) 1993-11-08
DE69306940T2 (de) 1997-06-26
SI9300149A (en) 1993-12-31
NO943571D0 (no) 1994-09-26
KR950700757A (ko) 1995-02-20
DK0633784T3 (da) 1997-01-20
IL105161A0 (en) 1993-07-08
SI9300149B (sl) 2003-02-28
AU767755B2 (en) 2003-11-20
KR100270134B1 (ko) 2000-10-16
FI944442A0 (fi) 1994-09-26
JPH07505372A (ja) 1995-06-15
SK115294A3 (en) 1995-06-07
JP3470719B2 (ja) 2003-11-25
SA93130573B1 (ar) 2004-08-31
CN1085805A (zh) 1994-04-27
EP0633784A1 (de) 1995-01-18
EP0633784B1 (de) 1996-12-27
WO1993019780A1 (en) 1993-10-14
DE69306940D1 (de) 1997-02-06
AP9300502A0 (en) 1993-04-30
UA44688C2 (uk) 2002-03-15
CA2132833C (en) 2007-03-06
ES2098029T3 (es) 1997-04-16
ATE146678T1 (de) 1997-01-15
MY111880A (en) 2001-02-28
SG48375A1 (en) 1998-04-17
NO309458B1 (no) 2001-02-05
SK280160B6 (sk) 1999-09-10
NO943571L (no) 1994-11-14
RU94042386A (ru) 1996-08-20
CZ283424B6 (cs) 1998-04-15
CN1072963C (zh) 2001-10-17
HU221253B1 (en) 2002-09-28
AU6445796A (en) 1996-11-07
DK0633784T4 (da) 2001-12-31
FI944442A (fi) 1994-09-26
IL105161A (en) 1998-08-16
MA22842A1 (fr) 1993-10-01
HUT69931A (en) 1995-09-28
EP0633784B2 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
ATE146678T1 (de) 3-0-deacyliertes monophosphoryl-lipid-a enthaltende hepatitis-impfstoffe
DK0812593T3 (da) Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
CY2007015I1 (el) Εμβολιο ιου θηλωματος
IL107445A0 (en) Anti-metastatic vaccine
IL79740A0 (en) Hepatitis vaccine
GB9213559D0 (en) Vaccines
GB9214871D0 (en) Vaccines
GB9202933D0 (en) Vaccines
GB9211081D0 (en) Vaccines
GB9020799D0 (en) Viral vaccines
GB9324964D0 (en) Viral vaccines
GB9305710D0 (en) Viral vaccines
GB9104903D0 (en) Viral vaccines
GB9124696D0 (en) Hepatitis c virus
GB8712042D0 (en) Virus & vaccine
GB9020584D0 (en) Vaccine
GB9218833D0 (en) Vaccines
GB9221891D0 (en) Vaccines
GB9217635D0 (en) Vaccines
GB9211318D0 (en) Vaccines
GB9226283D0 (en) Vaccines
GB9220360D0 (en) Vaccines
ZA935281B (en) Vaccines

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings